CNS PHARMACEUTICALS, INC. (CNSP): Price and Financial Metrics
CNSP Price/Volume Stats
Current price | $0.36 | 52-week high | $4.40 |
Prev. close | $0.37 | 52-week low | $0.23 |
Day low | $0.36 | Volume | 182,000 |
Day high | $0.39 | Avg. volume | 412,829 |
50-day MA | $0.36 | Dividend yield | N/A |
200-day MA | $1.41 | Market Cap | 2.25M |
CNSP Stock Price Chart Interactive Chart >
CNS PHARMACEUTICALS, INC. (CNSP) Company Bio
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.
Latest CNSP News From Around the Web
Below are the latest news stories about CNS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CNSP as an investment opportunity.
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of BerubicinIndependent DSMB recommends continuing clinical trial of Berubicin without modificationEnrollment expected to be complete in early Q1 2024HOUSTON, TX / ACCESSWIRE / December 18, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (CNS or the Company), ... |
CNS Pharmaceuticals files to sell 3.81M shares of common stockMore on CNS Pharmaceuticals... |
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No CureHOUSTON, TX / ACCESSWIRE / December 6, 2023 / Every form of cancer is devastating, but the unfortunate reality is not all cancers are created equal. There are certain forms of cancer that are more deadly. Glioblastoma (GBM) is a highly aggressive ... |
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of EfficacyData presented at the Society of NeuroOncology (SNO) 28th Annual MeetingBerubicin currently being evaluated in an ongoing potentially pivotal study for the treatment of Glioblastoma Multiforme (GBM)Topline result from preplanned interim futility analysis ... |
CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug CandidateHOUSTON, TX / ACCESSWIRE / November 16, 2023 / Glioblastoma is a highly aggressive type of brain cancer with no cure, leading to a grim prognosis and average survival time of only 14 to 16 months. With no approved treatment for recurrent GBM anywhere ... |
CNSP Price Returns
1-mo | 37.98% |
3-mo | -71.65% |
6-mo | -68.42% |
1-year | -63.27% |
3-year | -99.48% |
5-year | N/A |
YTD | -71.65% |
2023 | -47.08% |
2022 | -88.61% |
2021 | -60.54% |
2020 | -54.94% |
2019 | N/A |
Loading social stream, please wait...